Rib-X Pharmaceuticals Secures Funds

Rib-X Pharmaceuticals has closed the first tranche of a $67.5 million Series 2 preferred stock financing. A second tranche is anticipated to close around the end of 2012. The round was led by new investor Vatera Healthcare Partners and included existing shareholders Warburg Pincus, ABS Ventures and Vox Equity Partners.

North AmericaUSBriefs